Dysregulated NF-κB signaling has been associated with the development and progression of various types of cancer, including breast cancer, prostate cancer, and hematologic malignancies such as leukemia, lymphoma, and multiple myeloma [14]. This evidence concerns the gene NFKB1 and plasma cell myeloma.